People, November, 2011

Mover of the month

David Meeker has been made CEO of Genzyme, which was bought by Sanofi earlier in 2011, effective from November 1, 2011. Meeker will report to Christopher A Viehbacher, CEO of Sanofi, and joins the group management committee. Viehbacher remains chairman of Genzyme. Under Meeker's leadership, Genzyme will incorporate the rare disease business and the multiple sclerosis franchise. Meeker joined Genzyme in 1994 and was promoted to COO in 2009.

Eli Lilly is making key appointments due to the December 31 retirements of Bryce D Carmine and Frank Deane. Carmine led Lilly Bio-Medicines and Deane led global manufacturing operations. From January 1, Dave Ricks, president of Lilly USA, becomes senior vice president and president of Lilly Bio-Medicines. Previously he was general manager of Lilly affiliates in China and Canada. Ricks' responsibilities include the US, Japan and Europe. Maria Crowe, senior vice president for global drug product manufacturing, succeeds Deane as president of manufacturing operations. Alex Azar becomes president of Lilly USA.

CEO of Shire, Angus Russell, has joined the board of InterMune, Inc. as a non-executive director, with effect from October 31, 2011.

Amgen has appointed Anthony (Tony) Hooper as executive vice president, global commercial operations. It has also appointed Robert A Bradway to the board of directors. Hooper will report to Bradway, who is president and COO. Hooper joins after 16 years at Bristol-Myers Squibb (BMS) where he was most recently senior vice president, commercial operations and president, US, Japan and intercontinental. Bradway joined Amgen in 2006 as vice president, operations strategy, and served as executive vice president and chief financial officer from 2007 to 2010. 

Ralf Huss, previously global head of the Therapeutic Cell Initiative at Roche, has joined the management board of German-based Apceth. He is a Professor of Pathology and Adjunct Professor for Regenerative Medicine at Wake Forest Institute for Regenerative Medicine in Winston-Salem in the US.

Current president of generics firm, Mylan, Heather Bresch is set to become CEO, taking over from Robert Coury, who remains as executive chairman. Mylan COO Rajiv Malik, who joined the company with its buyout of Matrix Laboratories, takes Bresch's current job. Bresch was appointed to the board in March 2011.

France-based bio-pharmaceutical company Hybrigenics has appointed Dr Alain Munoz to its board of directors. Dr Munoz replaces Dr Bernhard Ehmer, president of ImClone Systems and will chair the clinical advisory board. He has over 20 years' experience in the pharmaceutical industry at senior management level with the Sanofi Group  and the French pharmaceutical company Fournier. 

Dr Angelika Bodenteich has been appointed head of development at Austrian company Marinomed Biotechnologie, which develops innovative therapies for respiratory diseases. She joins from Onepharm Research & Development and has more than 15 years of experience in the pharmaceutical industry. She is a trained pathologist who has worked in Austria, Norway and the US.

Medical technology industry organisation Eucomed has elected a new board of directors. Guy Lebeau (Johnson & Johnson) remains chairman, Roy Bridges (BD) remains vice-chair and Roland Pfleger (Covidien) joins Roy Bridges as vice-chair. Thierry Sarda (Smith & Nephew) remains treasurer. In addition to the three sector groups already represented, community care now has a seat on the board, represented by Klaus Grunau (Hollister). There are four other new members: Jose Calle Gordo (Abbott Vascular); Anna Lefevre Skjöldebrand (Swedish Medtech and
chair of the National Associations Network); Donald Munro (Rayner Intraocular Lenses) and Renaat Vermeulen (Biomet). 

The Drug Information Association (DIA) has appointed Kaushik Desai as director of DIA India. He has a deep knowledge of the global regulatory framework and the pharmaceutical environment in India and is a trained pharmacist.

Related links